[Effect of prodectin on the activity of the blood kallikrein-kinin system in diffuse toxic goiter].
Elevated activity of the blood kallikrein-kinin system with the predominance of kinin formation over inactivation was recorded in 65 patients with diffuse toxic goiter. The use of prodectin (pyridinolcarbamat), kinin antagonist, caused a decrease in the activities of the kallikrein-kinin system and improved the clinical course of the disease. The results obtained give evidence in favour of this preparation being included into the multiple modality treatment of diffuse toxic goiter.
D000293:Adolescent; D000328:Adult; D002219:Carbamates / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007610:Kallikreins / Q000097:blood*; D007705:Kinins / Q000037:antagonists & inhibitors / Q000097:blood*; D008297:Male; D011727:Pyridinolcarbamate / Q000627:therapeutic use*; D013971:Thyrotoxicosis / Q000097:blood / Q000188:drug therapy
D002219:Carbamates; D007705:Kinins; D011727:Pyridinolcarbamate; D007610:Kallikreins
Vliianie prodektina na aktivnost' kallikrein-kininovoĭ sistemy krovi pri diffuznom toksicheskom zobe.